A combination of the reported data demonstrates that NGF could be used inpatients with type 2 diabetes mellitus because of its ability to maintainβ-cell function, stimulate insulin secretion, and simultaneously impedethe development of diabetes mellitus and its comorbidities. The gene discussed is INS; the disease is type 2 diabetes mellitus.